343 related articles for article (PubMed ID: 25971209)
21. AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Ingle K; LaComb JF; Graves LM; Baines AT; Bialkowska AB
PLoS One; 2023; 18(11):e0294065. PubMed ID: 37943821
[TBL] [Abstract][Full Text] [Related]
22. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Zhang L; Yao J; Li W; Zhang C
Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
[TBL] [Abstract][Full Text] [Related]
23. RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
Duxbury MS; Ito H; Benoit E; Waseem T; Ashley SW; Whang EE
Clin Cancer Res; 2005 May; 11(9):3433-8. PubMed ID: 15867245
[TBL] [Abstract][Full Text] [Related]
24. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD
Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931
[TBL] [Abstract][Full Text] [Related]
25. Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.
Massihnia D; Avan A; Funel N; Maftouh M; van Krieken A; Granchi C; Raktoe R; Boggi U; Aicher B; Minutolo F; Russo A; Leon LG; Peters GJ; Giovannetti E
J Hematol Oncol; 2017 Jan; 10(1):9. PubMed ID: 28061880
[TBL] [Abstract][Full Text] [Related]
26. Tumor suppressive role of miR-33a-5p in pancreatic ductal adenocarcinoma cells by directly targeting RAP2A.
Lian Y; Jiang D; Sun J
Cell Mol Biol Lett; 2021 Jun; 26(1):24. PubMed ID: 34090323
[TBL] [Abstract][Full Text] [Related]
27. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
28. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
29. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
30. LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
Zhu YX; Li CH; Li G; Feng H; Xia T; Wong CH; Fung FKC; Tong JH; To KF; Chen R; Chen Y
Cell Mol Gastroenterol Hepatol; 2020; 10(4):811-828. PubMed ID: 32615164
[TBL] [Abstract][Full Text] [Related]
31. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma.
Wang L; Wang F; Na L; Yu J; Huang L; Meng ZQ; Chen Z; Chen H; Ming LL; Hua YQ
Cancer Biomark; 2018; 22(1):169-174. PubMed ID: 29526843
[TBL] [Abstract][Full Text] [Related]
32. MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
Lin Y; Ge X; Wen Y; Shi ZM; Chen QD; Wang M; Liu LZ; Jiang BH; Lu Y
Oncotarget; 2016 Oct; 7(43):70857-70868. PubMed ID: 27765914
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
34. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
35. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma.
Chen ZW; Hu JF; Wang ZW; Liao CY; Kang FP; Lin CF; Huang Y; Huang L; Tian YF; Chen S
J Exp Clin Cancer Res; 2022 Apr; 41(1):153. PubMed ID: 35459186
[TBL] [Abstract][Full Text] [Related]
36. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Jagadeeshan S; Subramanian A; Tentu S; Beesetti S; Singhal M; Raghavan S; Surabhi RP; Mavuluri J; Bhoopalan H; Biswal J; Pitani RS; Chidambaram S; Sundaram S; Malathi R; Jeyaraman J; Nair AS; Venkatraman G; Rayala SK
Ann Oncol; 2016 Aug; 27(8):1546-56. PubMed ID: 27117533
[TBL] [Abstract][Full Text] [Related]
37. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
38. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
[TBL] [Abstract][Full Text] [Related]
39. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
40. RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Yu C; Zhang X; Sun G; Guo X; Li H; You Y; Jacobs JL; Gardner K; Yuan D; Xu Z; Du Q; Dai C; Qian Z; Jiang K; Zhu Y; Li QQ; Miao Y
J Cell Mol Med; 2008 Dec; 12(6A):2334-49. PubMed ID: 18266952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
